Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

International phase III trial of Maxamine in malignant melanoma

Nov. 18, 1997

Evidence that Theratope elicits an antitumor cellular immune response presented

Nov. 18, 1997

FDA approves Intron A for non-Hodgkin's lymphoma

Nov. 12, 1997

AntiVirals to acquire ImmunoTherapy and its late-stage cancer vaccine

Nov. 7, 1997

Phase I trials begin on TNT in glioma patients

Nov. 6, 1997

Novopharm Biotech cleared for phase I trials of melanoma immunotherapy

Oct. 30, 1997

Antitumor activity of LC-9018 correlated with cytokine production

Oct. 28, 1997

KRN-7000 for the treatment of liver metastasis

Oct. 23, 1997

Imutec's Virulizin approved in Mexico for malignant melanoma

Oct. 23, 1997

Update on development of NeoPharm's novel chimeric human protein

Oct. 21, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
IMV-101 shows promise for B-cell malignancies
BioWorld Science
IMV-101 is a new CAR T-cell therapy targeting CD19 developed by Suzhou Immunofoco Biotechnology Co. Ltd. for the potential treatment of B-cell malignancies and...